In another major analysis, researchers examined more than 30 million FDA adverse event reports to identify potential safety signals linked to GLP-1 drugs
The Peptide Class Peptides are small proteins that function as messengers in the body
Proof is primarily preclinical, and clinical translation necessitates careful scrutiny
This concern has been investigated by the FDA, although the information has been limited, and mental health often has multiple potential causes
While the clinical impact of GLP-1s on approved indications (e.g., obesity, diabetes, cardiovascular risk) and adjacent indications is being studied extensively in clinical trials, there is limited scientific literature on GLP-1 use, efficacy or persistence outside of clinical trial settings